Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
暂无分享,去创建一个
[1] A. Brown. A composite score to predict short-term disease activity in patients with relapsing-remitting MS , 2008 .
[2] Chiara Romualdi,et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. , 2007, Archives of neurology.
[3] H. Schild,et al. Axonal Damage But No Increased Glial Cell Activity in the Normal-Appearing White Matter of Patients with Clinically Isolated Syndromes Suggestive of Multiple Sclerosis Using High-Field Magnetic Resonance Spectroscopy , 2007, American Journal of Neuroradiology.
[4] M. Filippi,et al. Associations between cervical cord gray matter damage and disability in patients with multiple sclerosis. , 2007, Archives of neurology.
[5] M. Filippi,et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. , 2007, Brain : a journal of neurology.
[6] A. Traboulsee. MRI relapses have significant pathologic and clinical implications in multiple sclerosis , 2007, Journal of the Neurological Sciences.
[7] M. Rovaris,et al. Diffusion Tensor MRI in Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[8] Marco Battaglini,et al. Measuring Brain Atrophy in Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[9] Robert Zivadinov,et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis , 2007, Multiple sclerosis.
[10] A. Kangarlu,et al. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. , 2007, AJNR. American journal of neuroradiology.
[11] J. De Keyser,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[12] F Träber,et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. , 2007, AJNR. American journal of neuroradiology.
[13] H P Hartung,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[14] M. Rovaris,et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. , 2006, Brain : a journal of neurology.
[15] M Rovaris,et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. , 2006, Brain : a journal of neurology.
[16] À. Rovira,et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes , 2006, Neurology.
[17] R. Rudick,et al. Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study , 2006, Annals of neurology.
[18] J A Frank,et al. MRI T2 lesion burden in multiple sclerosis , 2006, Neurology.
[19] M. Filippi,et al. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. , 2006, Archives of neurology.
[20] D. Goodin. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment? , 2006, Annals of neurology.
[21] O. Paulson,et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. , 2006, Archives of neurology.
[22] J. Aarseth,et al. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway , 2006, Neurology.
[23] G J Barker,et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. , 2005, Brain : a journal of neurology.
[24] M Rovaris,et al. Evidence for progressive gray matter loss in patients with relapsing-remitting MS , 2005, Neurology.
[25] Ponnada A Narayana,et al. Magnetic Resonance Spectroscopy in the Monitoring of Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[26] Marco Rovaris,et al. Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients , 2005, NeuroImage.
[27] Hans Lassmann,et al. Cortical lesions and brain atrophy in MS , 2005, Journal of the Neurological Sciences.
[28] A. J. Thompson,et al. Increasing normal–appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing–remitting multiple sclerosis , 2005, Journal of Neurology.
[29] Frederik Barkhof,et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. , 2005, AJNR. American journal of neuroradiology.
[30] G. Comi,et al. Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI , 2005, Neurology.
[31] Marco Rovaris,et al. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI , 2005, NeuroImage.
[32] M. Rovaris,et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. , 2005, AJNR. American journal of neuroradiology.
[33] G. Comi,et al. Imaging spinal cord damage in multiple sclerosis. , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[34] Uhc Campus. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study , 2005 .
[35] S. Rizvi,et al. Current approved options for treating patients with multiple sclerosis , 2004, Neurology.
[36] J. Rose,et al. Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody , 2004, Annals of neurology.
[37] D. Paty,et al. Interferon beta-1b in secondary progressive MS , 2004, Neurology.
[38] My-Van Au Duong,et al. Voxel‐based analysis of MTR images: A method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis , 2004, Journal of magnetic resonance imaging : JMRI.
[39] A. Achiron,et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. , 2004, Archives of neurology.
[40] David H. Miller,et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain , 2004, Annals of neurology.
[41] D. Goodin. Disease-modifying therapy in MS: a critical review of the literature , 2004, Journal of Neurology.
[42] M. Filippi,et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. , 2004, Archives of neurology.
[43] N. De Stefano,et al. Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment , 2004, Neurology.
[44] Guillermo Izquierdo,et al. Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy , 2004, BMC neurology.
[45] V. Durkalski,et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.
[46] S. Patten,et al. Minocycline reduces gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2004, Annals of neurology.
[47] David H. Miller,et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis , 2004, Journal of Neurology.
[48] F. Barkhof,et al. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite , 2004, Multiple sclerosis.
[49] D. Arnold,et al. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. , 2004, Archives of neurology.
[50] S. Hsieh,et al. Pharyngeal-brachial palsy after cytomegalovirus colitis , 2004, Neurology.
[51] R. Ordidge,et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis , 2003, Journal of Neurology.
[52] Marco Rovaris,et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. , 2003, Brain : a journal of neurology.
[53] Rohit Bakshi,et al. Thalamic Involvement in Multiple Sclerosis: A Diffusion‐Weighted Magnetic Resonance Imaging Study , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[54] Zhengrong Liang,et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients , 2003, Neurology.
[55] M Filippi,et al. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b , 2003, Neurology.
[56] P. M. Matthews,et al. Evidence of early cortical atrophy in MS , 2003, Neurology.
[57] F. Barkhof,et al. The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS , 2003, Neurology.
[58] Michael Wall,et al. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group , 2002, Neurology.
[59] Marco Rovaris,et al. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. , 2002, Archives of neurology.
[60] David H. Miller,et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.
[61] F. Barkhof. The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.
[62] Ponnada A Narayana,et al. Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain , 2002, Current opinion in neurology.
[63] Massimo Filippi,et al. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. , 2002, AJNR. American journal of neuroradiology.
[64] Zografos Caramanos,et al. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis , 2002, Journal of Neurology.
[65] M Filippi,et al. Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: Consensus report of the White Matter Study Group , 2002, Journal of magnetic resonance imaging : JMRI.
[66] Massimo Filippi,et al. MRI techniques to monitor MS evolution: The present and the future , 2002, Neurology.
[67] M. Rovaris,et al. Cognitive dysfunction in patients with mildly disabling relapsing–remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging , 2002, Journal of the Neurological Sciences.
[68] M. Filippi,et al. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients , 2002, Neurology.
[69] David H. Miller,et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.
[70] N. Richert. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". , 2002, Neurology.
[71] F. Barkhof,et al. The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS , 2001, Neurology.
[72] F Barkhof,et al. Optimizing the association between disability and biological markers in MS , 2001, Neurology.
[73] G. Comi,et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes” , 2001, Neurology.
[74] A. Thompson,et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. , 2001, Brain : a journal of neurology.
[75] C. Mainero,et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities , 2001, Neurology.
[76] F. Barkhof,et al. Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy , 2001, Journal of the Neurological Sciences.
[77] J K Udupa,et al. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. , 2001, AJNR. American journal of neuroradiology.
[78] M Cercignani,et al. Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis , 2001, Journal of neurology, neurosurgery, and psychiatry.
[79] M Cercignani,et al. Diffusion tensor magnetic resonance imaging in multiple sclerosis , 2001, Neurology.
[80] J L Ostuni,et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis , 2001, Multiple sclerosis.
[81] P M Matthews,et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.
[82] R. Grossman,et al. The accuracy of whole brain N-acetylaspartate quantification. , 2000, Magnetic resonance imaging.
[83] M. Rovaris,et al. Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis , 2000, Journal of neurology, neurosurgery, and psychiatry.
[84] G. Comi,et al. Magnetization transfer imaging to monitor the evolution of MS , 2000, Neurology.
[85] R Stollberger,et al. Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis , 2000, Magnetic resonance in medicine.
[86] G. Comi,et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. , 2000, AJNR. American journal of neuroradiology.
[87] S. Majumdar,et al. Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a , 2000, Neurology.
[88] F. Barkhof,et al. Magnetization Transfer Ratio of the Spinal Cord in Multiple Sclerosis: Relationship to Atrophy and Neurologic Disability , 2000, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[89] M Filippi,et al. Cladribine and progressive MS , 2000, Neurology.
[90] M Rovaris,et al. Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.
[91] M. Horsfield,et al. A conventional and magnetization transfer MRI study of the cervical cord in patients with MS , 2000, Neurology.
[92] G Cutter,et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. , 2000, Multiple sclerosis.
[93] F. Barkhof,et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.
[94] G. Comi,et al. Magnetization-transfer histogram analysis of the cervical cord in patients with multiple sclerosis. , 1999, AJNR. American journal of neuroradiology.
[95] G. Barker,et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H , 1999, Neurology.
[96] E. Cabanis,et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis , 1999, Neurology.
[97] M Rovaris,et al. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. , 1999, Current opinion in neurology.
[98] Ludwig Kappos,et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis , 1999, The Lancet.
[99] M Filippi,et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI , 1999, Neurology.
[100] J. Duyn,et al. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. , 1998, AJNR. American journal of neuroradiology.
[101] P M Matthews,et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.
[102] J K Udupa,et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS , 1998, Neurology.
[103] M Rovaris,et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis , 1998, Neurology.
[104] A. Thompson,et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.
[105] F. Barkhof,et al. Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis , 1998, Annals of neurology.
[106] A J Thompson,et al. MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences , 1998, Journal of neurology, neurosurgery, and psychiatry.
[107] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[108] O. Gefeller,et al. Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease , 1998, Annals of neurology.
[109] M Rovaris,et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis , 1997, Neurology.
[110] G. Comi,et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.
[111] A. Thompson,et al. Magnetisation transfer ratio measurement in the cervical spinal cord: a preliminary study in multiple sclerosis , 1997, Neuroradiology.
[112] A J Thompson,et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.
[113] A J Thompson,et al. Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.
[114] R S Balaban,et al. Magnetization transfer imaging: practical aspects and clinical applications. , 1994, Radiology.
[115] W. I. McDonald,et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.
[116] F. Barkhof,et al. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. , 1993, Brain : a journal of neurology.
[117] B E Kendall,et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.
[118] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.